News

Post hoc analysis of the topical therapy show patients receiving treatment for acne in the winter were as likely to achieve benefit as those receiving it in the summer.

The investigators found an adjusted odds ratio of 1.74 for hospitalized suicide attempts and 1.45 for those who committed suicide in individuals with recent psychiatric history.

Janssen reported significant benefit, and a tolerable profile, for the investigative drug that may become the first indicated to treat HDFN.

In this interview, Dr. Noor spoke about the contents of his conference presentation regarding the tailoring of treatment plans to patients with skin of color.

In her presentation ‘Treatment of Eczema in Pediatric Patients Under 12 Years,’ Dr. Garza-Mayers spoke on considerations for atopic dermatitis management.

At ADA 2023, we sat down with W. Timothy Garvey, MD, to learn more about the safety and efficacy of tirzepatide in the SURMOUNT-2 trial and how the results complement SURMOUNT-1.

An analysis at ADA 2023 presents novel findings on the inverse association between clinical and biochemical factors in diabetic retinopathy and age-related macular degeneration.

Often overlooked and unrecognized, the mental health challenges accompanying type 1 diabetes are becoming a focal point of discussion for many in the field, including Mark Heyman, PhD, who joined Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special ADA 2023 edition of Diabetes Dialogue.

In an interview at ADA 2023, Aggarwal discusses the efficacy of sotagliflozin on heart failure-related outcomes independent of A1c and the greater implications of these findings.

A new analysis from ADA 2023 suggests positive discordance according to GMI/A1c ratios was associated with an increased risk for diabetic retinopathy.

At ADA 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with ADCES President-Elect Jane Dickinson, RN, PhD, to discuss her work to address shortfalls of the current language used in the management of diabetes.

Data from a pair of phase 3a trials presented at ADA 2023 provide clinicians with new insight into the effects of once-weekly insulin icodec relative to daily insulin degludec and insulin glargine U100.

At ADA 2023, hosts sit down with Gary Rothenberg, DPM, to discuss awareness and management of diabetic foot ulcers as well as how social determinants of health can influence risk and outcomes for patients with diabetes.

At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.

An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.

New results from the ongoing clinical trial of VX-880 suggested all patients with T1D treated with the novel stem cell-derived islet cell therapy showed restored endogenous insulin secretion and improved glycemic control.

According to new data presented at ADA 2023, patients with T2D experience an increased risk of incident retinopathy per 1-SD increase in glycemia risk index.

Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.

A new analysis presented at ADA 2023 suggests a machine learning algorithm may refine the risk of diabetic retinopathy progression and personalize screening intervals for patients.

A post hoc analysis of phase 3 adds support to the IL-17A inhibitor for the potential treatment of HS.

While contact dermatitis is difficult to distinguish in children, there has become a greater collaboration between allergic and dermatologic specialists in managing conditions like atopic dermatitis.

The first triple-combination topical drug for acne may be available by the end of this year. One expert has high hopes for it.

Zirwas touts topical ruxolitinib's rapid, effective treatment of atopic dermatitis, and reviews the safety outcomes associated with JAK inhibitors.

Pigmentary disorders including melasma are difficult to treat and complex. The leading agent for one expert was uncovered by unique circumstances.

Describing the biggest takeaways from her talk ‘Diagnosis and Management of Blistering Disorders,’ Dr. Noe went in depth about treatment of blistering in patients.

This interview with Dr. Noe at the SDPA conference featured a discussion about her background and her presentation titled ‘Diagnosis and Management of Blistering Disorders.'

From addressing the rare acne fulminans to utilizing narrow-spectrum antibiotics, the modern field of acne treatment is more complicated than it seems.

A pair of phase 2 trials presented at ADA 2023 detail the body weight lowering and glycemic control benefits of orforglipron, an oral GLP-1 RA developed by Eli Lilly and Company.

In another interview segment, Dr. Amin described some of the other biggest points from his conference talk on choosing the best route for psoriasis in patients.

In this interview segment, Dr. Amin described some of the major takeaways from his conference talk titled ‘Biological Bootcamp: How to Select the Best Biologics for Your Psoriasis Patient.’